ClinicalTrials.gov record
Completed Phase 3 Interventional

Effects of Antidepressants on Sexual Functioning

ClinicalTrials.gov ID: NCT00051259

Public ClinicalTrials.gov record NCT00051259. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 6:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Effects on Sexual Functioning of Extended-Release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients With Moderate to Severe Major Depression Over an Eight-Week Treatment Period

Study identification

NCT ID
NCT00051259
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
420 participants

Conditions and interventions

Interventions

  • Extended-Release Bupropion Hydrochloride Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2002
Primary completion
May 31, 2004
Completion
May 31, 2004
Last update posted
Oct 3, 2010

2003 – 2004

United States locations

U.S. sites
23
U.S. states
14
U.S. cities
23
Facility City State ZIP Site status
GSK Investigational Site Berkeley California 94709
GSK Investigational Site Beverly Hills California 90210
GSK Investigational Site La Mesa California 91942
GSK Investigational Site Oceanside California 92056
GSK Investigational Site Coral Springs Florida 33065
GSK Investigational Site Jacksonville Florida 32216
GSK Investigational Site Indianapolis Indiana 46202
GSK Investigational Site Terre Haute Indiana 47802
GSK Investigational Site Baltimore Maryland 21208
GSK Investigational Site Rockville Maryland 20852
GSK Investigational Site Minneapolis Minnesota 55454
GSK Investigational Site New York New York 10021
GSK Investigational Site Cleveland Ohio 44109
GSK Investigational Site Toledo Ohio 43623
GSK Investigational Site Tulsa Oklahoma 74135
GSK Investigational Site Eugene Oregon 97401
GSK Investigational Site Portland Oregon 97210
GSK Investigational Site Lincoln Rhode Island 02865-4208
GSK Investigational Site Charleston South Carolina 29407
GSK Investigational Site Bellaire Texas 77401
GSK Investigational Site Charlottesville Virginia 22908
GSK Investigational Site Richmond Virginia 23294
GSK Investigational Site Madison Wisconsin 53719

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00051259, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 3, 2010 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00051259 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →